{"id":745189,"date":"2015-05-29T13:06:00","date_gmt":"2015-05-29T13:06:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/"},"modified":"2025-11-07T01:25:09","modified_gmt":"2025-11-07T06:25:09","slug":"new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/","title":{"rendered":"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status"},"content":{"rendered":"<p class=\"bwalignc\">       Results from KEYNOTE-012, the First and Largest Study to Date of an        Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO        Annual Meeting     <\/p>\n<p class=\"bwalignc\">       KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in        Heavily Pre-treated Patients     <\/p>\n<p class=\"bwalignc\">       Merck is Advancing a Broad Head and Neck Clinical Program for        KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and        in Combination with Other Agents     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced new investigational data evaluating KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy from<br \/>\n      the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with<br \/>\n      recurrent or metastatic head and neck cancer, regardless of PD-L1<br \/>\n      expression status. In the evaluable patients, the overall response rate<br \/>\n      (ORR) (confirmed and unconfirmed) was 24.8 percent for KEYTRUDA (200 mg<br \/>\n      fixed dose every three weeks) (n=29\/117) (95% CI, 17.3-33.6). When<br \/>\n      looking at HPV status, the ORR was similar among HPV-positive and<br \/>\n      HPV-negative disease (20.6 percent [n=7\/34] and 27.2 percent [n=22\/81],<br \/>\n      respectively) (95% CI, 8.7-37.9 and 17.9-38.2). These data, featured in<br \/>\n      the ASCO Press Program today, will be presented in an oral session by<br \/>\n      Dr. Tanguy Seiwert, The University of Chicago, on Monday, June 1 at the<br \/>\n      51<sup>st<\/sup> Annual Meeting of the American Society of Clinical<br \/>\n      Oncology (ASCO) in Chicago (Abstract #LBA6008).\n    <\/p>\n<p>\n      Merck has initiated a comprehensive clinical development program for<br \/>\n      KEYTRUDA evaluating a fixed dosing regimen (200 mg every three weeks) in<br \/>\n      head and neck cancer across multiple lines of therapy as monotherapy and<br \/>\n      in combination with chemotherapy and other agents. Results from<br \/>\n      KEYNOTE-012 were first presented at the 2014 ASCO Annual Meeting and<br \/>\n      showed 19.6 percent ORR for KEYTRUDA (10 mg\/kg every two weeks) in<br \/>\n      heavily pre-treated patients with advanced head and neck cancer with<br \/>\n      tumor cells positive for PD-L1 expression.\n    <\/p>\n<p>\n      &#8220;Advanced head and neck cancer is a severe and life-altering condition.<br \/>\n      Unfortunately we have few effective treatment options, particularly for<br \/>\n      patients whose disease is not responding to current therapies,&#8221; said Dr.<br \/>\n      Seiwert. \u201cAs a practicing oncologist, I am very encouraged by the<br \/>\n      durable responses demonstrated with pembrolizumab in this study, and<br \/>\n      look forward to data being shared in the future from the additional<br \/>\n      confirmatory studies now being conducted in advanced head and neck<br \/>\n      cancer.&#8221;\n    <\/p>\n<p>\n      \u201cThe totality of the data presented at ASCO furthers our understanding<br \/>\n      of the clinical potential of KEYTRUDA in head and neck cancer,<br \/>\n      regardless of PD-L1 expression or HPV status,\u201d said Dr. Roger Dansey,<br \/>\n      senior vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories. \u201cBased on the results observed<br \/>\n      to date, we are advancing multiple registrational studies in head and<br \/>\n      neck cancer including randomized evaluations of overall survival and<br \/>\n      progression-free survival with KEYTRUDA, as monotherapy and in<br \/>\n      combination with chemotherapy, compared to standard of care.\u201d\n    <\/p>\n<p>\n      <b>Additional Results from KEYNOTE-012 in Advanced Head and Neck Cancer<\/b>\n    <\/p>\n<p>\n      Additional findings from KEYNOTE-012, the first and largest Phase 1b<br \/>\n      study of an anti-PD-1 therapy in advanced head and neck cancer, showed<br \/>\n      tumor shrinkage was achieved in 56 percent of total evaluable patients<br \/>\n      who had measurable disease with one post baseline scan (n=59\/106). The<br \/>\n      median duration of response was not reached (7.3+ &#8211; 25.1+ weeks among<br \/>\n      patients with a confirmed response), with a median follow up duration of<br \/>\n      5.7 months (0.2 \u2013 8.7 months). At the time of the analysis, 86 percent<br \/>\n      of patients who responded continued to respond to treatment (n=25\/29).<br \/>\n      The data are based on an analysis conducted with a cut-off of March 23,<br \/>\n      2015.\n    <\/p>\n<p>\n      Adverse events in the study were consistent with previously reported<br \/>\n      safety data for KEYTRUDA (n=132). The most common treatment-related<br \/>\n      adverse events (occurring in greater than or equal to 5% of patients)<br \/>\n      included: fatigue (15.2%), hypothyroidism (9.1%), decreased appetite<br \/>\n      (7.6%), rash (7.6%), dry skin (6.8%), and pyrexia (6.8%). Some patients<br \/>\n      experienced adverse events of special interest, including hypothyroidism<br \/>\n      (10.6%), pneumonitis (3.0%), thyroiditis (2.3%), colitis (0.8%),<br \/>\n      interstitial lung disease (0.8%), acquired epidermolysis bullosa (0.8%),<br \/>\n      drug induced liver injury (0.8%), epidermolysis (0.8%), and diabetic<br \/>\n      ketoacidosis (0.8%). Four patients experienced adverse events of special<br \/>\n      interest that resulted in treatment discontinuation. There were no<br \/>\n      treatment-related deaths.\n    <\/p>\n<p>\n      <b>About the KEYNOTE-012 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-012 is an ongoing multi-center, non-randomized Phase 1b trial<br \/>\n      evaluating the safety, tolerability and anti-tumor activity of KEYTRUDA<br \/>\n      monotherapy (10 mg\/kg every two weeks or 200 mg IV every three weeks) in<br \/>\n      patients with advanced triple negative breast cancer (TNBC), advanced<br \/>\n      head and neck cancer, advanced urothelial cancer, or advanced gastric<br \/>\n      cancer. The primary endpoints of the study include overall safety,<br \/>\n      tolerability, and anti-tumor activity (as measured by RECIST v1.1);<br \/>\n      secondary endpoints include progression-free survival (PFS), overall<br \/>\n      survival (OS), and duration of response.\n    <\/p>\n<p>\n      <b>About Head and Neck Cancer<\/b>\n    <\/p>\n<p>\n      Head and neck cancer describes a number of different tumors that develop<br \/>\n      in or around the throat, larynx, nose, sinuses and mouth. Most head and<br \/>\n      neck cancers are squamous cell carcinomas that begin in the flat,<br \/>\n      squamous cells that make up the thin surface layer of the structures in<br \/>\n      the head and neck. The leading modifiable risk factors for head and neck<br \/>\n      cancer include tobacco and heavy alcohol use. Other non-modifiable risk<br \/>\n      factors include infection with certain types of HPV, also called&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cancer.gov%2FCommon%2FPopUps%2FpopDefinition.aspx%3Fid%3DCDR0000045714%26version%3DPatient%26language%3DEnglish&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=human+papillomaviruses&amp;index=1&amp;md5=aa001c78f9a27624013a42c100293a27\" rel=\"nofollow\">human<br \/>\n      papillomaviruses<\/a>. Each year there are approximately 400,000 cases of<br \/>\n      cancer of the oral cavity and pharynx, in addition to approximately<br \/>\n      160,000 cancers of the larynx, resulting in approximately 300,000 deaths.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 100 clinical trials \u2013 across more than 30<br \/>\n      tumor types and enrolling more than 16,000 patients \u2013 both as a<br \/>\n      monotherapy and in combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=1c2ccca52338d1633de5bd2cddc32699\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=bc36ce9ddeba24fcb8b5ffa6cf2f2277\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=e85541ac05bad67b21016a79f1654233\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=07c35ac29271ec856a7265dc81bf3782\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=aaf0185e5d9c7d58ef1b1e44de4c3fc1\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=4c08bf05397182b2a33b0aa1972653a0\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=d920eafb40092d3d864f4c8d3a5777a6\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><br \/>\n      and the Medication Guide for KEYTRUDA at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51112609&amp;newsitemid=20150529005966&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=e9c12bcf766cc28963129da381a5413f\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a>.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150529005966r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-664-0282<br \/>Claire Mulhearn,        908-200-1889<br \/>or<br \/>Investors:<br \/>Joseph Romanelli, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. In the evaluable patients, the overall response rate (ORR) (confirmed and unconfirmed) was 24.8 percent for KEYTRUDA (200 mg fixed dose every three weeks) (n=29\/117) (95% CI, 17.3-33.6). When looking at HPV status, the ORR was similar among HPV-positive and HPV-negative disease (20.6 percent [n=7\/34] and 27.2 percent [n=22\/81], respectively) (95% CI, 8.7-37.9 and 17.9-38.2). These data, featured in the ASCO Press Program today, will be presented in an oral session by Dr. Tanguy Seiwert, The University of Chicago, on Monday, June 1 at the 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745189","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. In the evaluable patients, the overall response rate (ORR) (confirmed and unconfirmed) was 24.8 percent for KEYTRUDA (200 mg fixed dose every three weeks) (n=29\/117) (95% CI, 17.3-33.6). When looking at HPV status, the ORR was similar among HPV-positive and HPV-negative disease (20.6 percent [n=7\/34] and 27.2 percent [n=22\/81], respectively) (95% CI, 8.7-37.9 and 17.9-38.2). These data, featured in the ASCO Press Program today, will be presented in an oral session by Dr. Tanguy Seiwert, The University of Chicago, on Monday, June 1 at the 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\\\/\",\"name\":\"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-05-29T13:06:00+00:00\",\"dateModified\":\"2025-11-07T06:25:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/","og_locale":"en_US","og_type":"article","og_title":"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. In the evaluable patients, the overall response rate (ORR) (confirmed and unconfirmed) was 24.8 percent for KEYTRUDA (200 mg fixed dose every three weeks) (n=29\/117) (95% CI, 17.3-33.6). When looking at HPV status, the ORR was similar among HPV-positive and HPV-negative disease (20.6 percent [n=7\/34] and 27.2 percent [n=22\/81], respectively) (95% CI, 8.7-37.9 and 17.9-38.2). These data, featured in the ASCO Press Program today, will be presented in an oral session by Dr. Tanguy Seiwert, The University of Chicago, on Monday, June 1 at the 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:09+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/","name":"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-05-29T13:06:00+00:00","dateModified":"2025-11-07T06:25:09+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-durable-anti-tumor-activity-with-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-advanced-head-and-neck-cancer-regardless-of-pd-l1-expression-sta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"267c90b8-fd9e-4967-9a50-6c5f92c5d8cd","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Findings-Show-Durable-Anti-Tumor-Activity-with-KEYTRUDA-pembrolizumab-Mercks-Anti-PD-1-Therapy-in-Patients-with-Advanced-Head-and-C1U3J.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745189\/revisions"}],"predecessor-version":[{"id":3674636,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745189\/revisions\/3674636"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745189"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}